ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2024 - 2026)
ARS Pharmaceuticals (SPRY) posted Goodwill & Intangibles of $14.2 million for Q1 2026, down 1.91% sequentially from $14.5 million in Q4 2025, and up 5547.81% YoY from $251000.0 in Q1 2025.
ARS Pharmaceuticals (SPRY) Goodwill & Intangibles (2024 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Goodwill & Intangibles for 3 years, with the latest figure at $14.2 million in Q1 2026.
- Quarterly Goodwill & Intangibles rose 5547.81% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 5547.81% YoY) and the FY2025 annual result came in at $14.5 million, up 96.07% from the prior year.
- Goodwill & Intangibles slipped to $14.2 million in Q1 2026 per SPRY's latest filing, from $14.5 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $14.5 million in Q4 2025 and troughed at $125000.0 in Q3 2025.
- A 3-year average of $8.2 million and a median of $10.2 million in 2024 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2025 and 2026: Goodwill & Intangibles jumped 96.07% in 2025, then jumped 5547.81% in 2026.
- Over 3 years, Goodwill & Intangibles stood at $7.4 million in 2024, then surged by 96.07% to $14.5 million in 2025, then declined by 1.91% to $14.2 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $14.2 million, $14.5 million, and $125000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.90 Mn |
| Mar 31, 2026 | 14.18 Mn |
| Dec 31, 2025 | 14.45 Mn |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 12.97 Mn |
| Mar 31, 2025 | 251,000.00 |
| Dec 31, 2024 | 7.37 Mn |